BL-B01D1 Shows Promise in Advanced Squamous Esophageal Carcinoma
Table of Contents
Recent phase I clinical trial data indicates that the antibody-drug conjugate (ADC) BL-B01D1 demonstrates encouraging efficacy and a manageable safety profile in patients with previously treated advanced squamous esophageal carcinoma (ESCC).The study, led by researchers at Peking University Cancer hospital and Institute, evaluated the drug’s performance in 82 patients. https://www.biosciencetrends.com/news/bl-b01d1-shows-promising-anti-tumor-activity-in-escc-patients/
Understanding Squamous Esophageal carcinoma (ESCC)
Esophageal cancer is a malignancy arising in the esophagus – the tube that carries food from the throat to the stomach. Squamous cell carcinoma (SCC) is a major histological subtype, particularly prevalent in asia and among individuals with a history of tobacco and alcohol use. https://www.cancer.org/cancer/esophageal-cancer/about/what-is-esophageal-cancer.html Advanced ESCC presents a meaningful clinical challenge, with limited treatment options available after initial therapies fail.Immunotherapy has shown some benefit, but resistance and progression remain concerns.
BL-B01D1: A Novel Antibody-Drug Conjugate
BL-B01D1 is a first-in-class ADC designed to target ESCC cells.It consists of a bispecific antibody that recognizes both EGFR (Epidermal Growth Factor Receptor) and HER3 (Human Epidermal Growth Factor Receptor 3). This antibody is linked to a topoisomerase I inhibitor, a chemotherapy drug that disrupts DNA replication, via a cleavable linker.The bispecific antibody aims to enhance targeted delivery of the chemotherapy directly to cancer cells, minimizing damage to healthy tissues. https://www.biosciencetrends.com/news/bl-b01d1-shows-promising-anti-tumor-activity-in-escc-patients/
Phase I Trial Results: Efficacy and Dosage
The phase I study investigated two dosage levels of BL-B01D1: 2.0 mg/kg and 2.5 mg/kg, administered intravenously every three weeks (Q3W). Key findings include:
* Objective Response Rate (cORR): Across all 82 patients, the cORR was 29.3% (24 of 82). For patients evaluable for response (73 patients),the cORR was 32.9% (24 of 73).
* Dose-Dependent Response: The 2.5 mg/kg dose group exhibited a higher cORR of 39.6% (21 of 53) and a disease control rate (DCR) of 79.2% (42 of 53). The 2.0 mg/kg group had a cORR of 15.0% (3 of 20) and a DCR of 50.0% (10 of 20).
* Recommended Phase II Dose: Based on the efficacy and safety data, the researchers established the recommended dose for phase II studies at 2.5 mg/kg D1D8 Q3W. https://www.biosciencetrends.com/news/bl-b01d1-shows-promising-anti-tumor-activity-in-escc-patients/
Safety Profile and Adverse Events
While BL-B01D1 demonstrated promising efficacy, it also exhibited a notable safety profile.
* Grade 3 adverse Events: The incidence of grade 3 (severe) treatment-emergent adverse events was 63.3% in the 2.5 mg/kg group.
* Common Adverse Events: The most frequently reported grade 3 adverse events included anemia (28.3%), leukopenia (18.3%), thrombocytopenia (18.3%),and neutropenia (16.7%).
* Interstitial Lung Disease: Two cases of grade 3 interstitial lung disease (ILD) were reported.